Aptose presents tuspetinib triplet therapy data at ASH: 100% CR/CRh at higher doses in AML

Aptose Biosciences Inc.

90% CR/CRh across all doses (40/80/120 mg TUS); 100% at 80 mg and 120 mg levels.
78% of responders achieved MRD negativity by central flow cytometry.
No dose-limiting toxicities or drug-related deaths; febrile neutropenia in 2 subjects (16.7%).
Responses seen in FLT3-WT, TP53/complex karyotype, RAS, and MDS-related mutations.
Preliminary data at 160 mg cohort show early blast clearance and MRD negativity.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.